Impact of TP53 clonal clearance on OS with HMA therapy and allo-HCT. (A) Impact of TP53 clonal clearance on OS in all HMA-treated patients undergoing sequential molecular profiling (median OS, 15.6 months with TP53 clearance and 7.7 months with TP53 persistence). (B) OS of all patients within the cohort proceeding to allo-HCT after first-line therapy with an HMA. (C) Impact of TP53 clonal clearance on OS among patients proceeding to allo-HCT (median OS, 25.2 vs 11.7 months, respectively). Comparison of OS among patients proceeding to allo-HCT vs patients receiving HMA therapy alone in those with TP53 clonal clearance before transplant (25.2 vs 7.7 months) (D) vs those with TP53 clonal persistence (11.7 vs 7.7 months) (E).